Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Things are going great. GE Aerospace stock trades for about 38 times estimated 2025 earnings and 32 times estimated 2026 earnings. History is no help: The company has only been independent since its ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...

Airbnb stock surged after fourth-quarter earnings beat expectations. It has largely missed out on the travel boom but that may be about to change as the short-term rental company positions its app to ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care ...